We encourage you to read the publication available in Frontiers in Pharmacology, co-authored by Robert Plisko, president of HTA Consulting: "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures".Full text of the
Dr Magdalena Władysiuk, Vice President of HTA Consulting, gave an interview for Health Policy about the lack of a national plan for rare diseases.We encourage you to read the article and view the entire interview at the PZ website [Polish only].
HTA Consulting assessed the availability of orphan drugs with high unmet need (non-oncological drugs, the only one with orphan status registered after 2012 by EMA). Results from 32 countries were obtained - all EU and EFTA countries were analyzed except Cyprus (as of 10/04/2018)Average number
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.